Corteva
CTVA
$89.25
+0.53%
Corteva is an agricultural inputs pure play, formed in 2019 from the DowDuPont merger, that develops and sells seeds and crop protection products globally. As a leader in seed innovation and crop protection, the company differentiates itself through its strong R&D pipeline and integrated product portfolio serving farmers worldwide. The current investor narrative centers on Corteva's planned late-2026 spin-off of its seeds business into a new entity called Vylor, which will leave the remaining crop protection business as a pure-play company. This strategic transformation, combined with recent strong quarterly earnings and a rising stock price, has driven significant attention and debate around the stock's future growth trajectory and valuation.…
CTVA
Corteva
$89.25
CTVA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corteva's 12-month outlook, with a consensus price target around $91.10 and implied upside of +2.1% versus the current price.
Average Target
$91.10
0 analysts
Implied Upside
+2.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$77 - $103
Analyst target range
Corteva is covered by 20 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.81 on a 1-5 scale, where 1 is Strong Buy). The average target price is $90.20, implying approximately +3.3% upside from the current price of $87.30. The distribution shows a bullish lean, with no sell ratings in the recent institutional ratings data, which includes ratings from Mizuho (Outperform), Barclays (Overweight), Morgan Stanley (Overweight), RBC Capital (Outperform), and Oppenheimer (Outperform), among others. The target price range spans from a low of $77.00 to a high of $100.00. The high target of $100.00 assumes successful execution of the seeds spin-off and continued growth in crop protection, while the low target of $77.00 prices in potential execution risks or a downturn in agricultural demand. The spread of $23 (23% of the average) indicates moderate uncertainty, but the consistent 'Outperform' and 'Overweight' ratings from major firms suggest strong conviction in the stock's prospects. Recent ratings have been reaffirmed without downgrades, signaling stability in analyst sentiment.
Drowning in data?
Find the real signal!
Bulls vs Bears: CTVA Investment Factors
Corteva presents a balanced investment case with strong revenue growth, margin expansion, and a solid balance sheet supporting the upcoming spin-off. The bull case is anchored by 11.1% revenue growth, improving gross margins, and a forward P/E in line with industry peers. However, the trailing P/E of 41.6x is expensive, seasonal earnings volatility persists, and the spin-off introduces execution risk. The most critical tension is whether the company can deliver the earnings growth implied by the forward P/E—if it does, the stock could re-rate higher; if not, multiple compression could erase gains. Currently, the evidence slightly favors the bull case given the strong Q1 performance and analyst support, but the limited upside to the average target suggests a cautious approach.
Bullish
- Strong Q1 2026 Revenue Growth: Q1 2026 revenue of $4.905 billion grew 11.1% year-over-year from $4.417 billion, driven by both seeds and crop protection segments. This growth outpaces the agricultural sector average and demonstrates robust demand for Corteva's integrated product portfolio.
- Healthy Gross Margin Expansion: Gross margin improved to 48.5% in Q1 2026 from 47.0% in Q1 2025, reflecting better cost management and pricing power. The operating margin of 23.7% in Q1 2026 is well above the industry average for agricultural inputs.
- Low Debt and Strong Liquidity: Debt-to-equity ratio is only 0.107, and the current ratio stands at 1.43, indicating a very strong balance sheet. This financial flexibility supports the planned spin-off of the seeds business and potential dividend growth.
- Attractive Forward Valuation: Forward P/E of 21.2x is in line with the industry average of ~22x, suggesting the stock is reasonably priced on expected earnings. The P/S ratio of 2.6x is well below its historical average of ~9x, indicating potential upside on a sales basis.
Bearish
- High Trailing P/E Multiple: Trailing P/E of 41.6x is an 89% premium to the industry average of 22x, reflecting elevated expectations. If earnings fail to meet growth projections, the stock could face multiple compression and significant downside.
- Seasonal Earnings Volatility: Corteva reports losses in Q3 and Q4 due to the agricultural cycle, with Q4 2025 net loss of $552 million and Q3 2025 loss of $320 million. This cyclicality can lead to negative surprises and investor uncertainty.
- Spin-Off Execution Risk: The planned late-2026 spin-off of the seeds business (Vylor) introduces complexity and potential disruption. Execution missteps, regulatory hurdles, or unfavorable market conditions could impair value creation.
- Modest Analyst Upside: The average analyst target of $90.20 offers only +3.3% upside from the current price of $87.30, which is limited. The stock is already near the 52-week high of $88.22, suggesting much of the good news may be priced in.
CTVA Technical Analysis
Corteva is in a sustained uptrend, with the stock price up 19.3% over the past year and currently trading at $87.30, near the top of its 52-week range of $60.54 to $88.22 (99.0% of the range). This positioning near the high end suggests strong bullish momentum, though it also raises caution about potential overextension. The stock's beta of 0.56 indicates it is significantly less volatile than the broader market, making it a relatively defensive holding within the agricultural sector. Short-term momentum is accelerating sharply, with a 1-month price change of +12.8% and a 3-month change of +8.7%, both outpacing the S&P 500's respective gains of 0.3% and 4.7%. The 1-month relative strength of +12.5% confirms strong recent outperformance. This short-term acceleration aligns with the longer-term uptrend, suggesting no divergence, but the rapid pace may invite profit-taking. Key technical support lies near the 52-week low of $60.54, while resistance is at the 52-week high of $88.22. A breakout above $88.22 would signal a continuation of the uptrend and likely attract further buying, while a breakdown below recent support around $75 could indicate a trend reversal. With a beta of 0.56, Corteva is 44% less volatile than the market, which may appeal to risk-averse investors but also limits upside in strong market rallies.
Beta
0.56
0.56x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$61-$89
Price range past year
Annual Return
+22.1%
Cumulative gain past year
| Period | CTVA Return | S&P 500 |
|---|---|---|
| 1m | +11.4% | +0.8% |
| 3m | +11.8% | +3.5% |
| 6m | +24.5% | +7.2% |
| 1y | +22.1% | +16.5% |
| ytd | +31.7% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTVA Fundamental Analysis
Corteva's revenue trajectory is growing, with Q1 2026 revenue of $4.905 billion, up 11.1% year-over-year from $4.417 billion in Q1 2025. The multi-quarter trend shows a clear seasonal pattern, with Q2 typically being the strongest quarter (e.g., $6.456 billion in Q2 2025), but the year-over-year growth in Q1 2026 is encouraging. Revenue segments reveal that Seeds contribute the majority ($3.023 billion in the latest quarter) versus Crop Protection ($1.882 billion), with Herbicides ($1.027 billion) being the largest crop protection category. The growth trajectory supports the investment case, though the upcoming spin-off introduces uncertainty about future revenue composition. Profitability is solid, with Q1 2026 net income of $720 million and a gross margin of 48.5%, up from 47.0% in Q1 2025. The operating margin of 23.7% in Q1 2026 is healthy and above the industry average for agricultural inputs. However, the company has experienced seasonal losses in Q3 and Q4 (e.g., net loss of $552 million in Q4 2025), which is typical for the agricultural cycle. The trailing twelve-month net margin is 6.3%, reflecting the impact of those seasonal losses. The balance sheet is strong, with a debt-to-equity ratio of only 0.107 and a current ratio of 1.43, indicating ample liquidity. Free cash flow over the trailing twelve months is $2.046 billion, though Q1 2026 showed negative free cash flow of -$2.972 billion due to seasonal working capital build. The ROE of 4.5% is modest but consistent with the capital-intensive nature of the agricultural industry. Overall, Corteva generates sufficient cash to fund operations and growth internally, with low financial risk.
Quarterly Revenue
$4.9B
2026-03
Revenue YoY Growth
+11.1%
YoY Comparison
Gross Margin
48.5%
Latest Quarter
Free Cash Flow
$2.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTVA Overvalued?
Since net income is positive (TTM net income of $720 million in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E stands at 41.6x, while the forward P/E is 21.2x, implying the market expects significant earnings growth in the coming year. The gap between trailing and forward P/E suggests that the market is pricing in a strong recovery from the seasonal losses in late 2025. Compared to the industry average P/E of approximately 22x (based on sector data), Corteva's trailing P/E of 41.6x represents a 89% premium, but the forward P/E of 21.2x is in line with the industry. This indicates that the premium is driven by expectations of future earnings growth, which may be justified by the company's leading market position and the upcoming spin-off catalyst. Historically, Corteva's trailing P/E has ranged from around 8x to over 250x over the past five years, with the current 41.6x near the higher end of its historical band. The forward P/E of 21.2x is closer to the historical median, suggesting that while the stock is not cheap on a trailing basis, the forward valuation is more reasonable. The P/S ratio of 2.6x is below the historical average of around 9x, indicating that on a sales basis, the stock is relatively inexpensive compared to its own history.
PE
41.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Corteva's primary financial risk is its high trailing P/E of 41.6x, which leaves little room for error. If earnings growth disappoints, the stock could suffer multiple compression. Additionally, the company's seasonal losses in Q3 and Q4 (e.g., net loss of $552 million in Q4 2025) create earnings volatility and may unsettle investors. While debt is low, the negative free cash flow of -$2.972 billion in Q1 2026 due to seasonal working capital build is a temporary but notable cash flow risk. The ROE of 4.5% is modest, indicating that the company is not generating exceptional returns on equity relative to its valuation.
Market & Competitive Risks: Corteva faces valuation compression risk if the market re-rates the stock to a lower multiple, especially if agricultural commodity prices decline. The stock's beta of 0.56 provides some downside protection, but it also means less upside in strong markets. Competitive threats from other seed and crop protection companies (e.g., Bayer, Syngenta) could pressure margins. The upcoming spin-off may distract management and create regulatory risks. With the stock near its 52-week high, any negative news could trigger profit-taking.
Worst-Case Scenario: If the spin-off faces delays or fails to unlock value, and agricultural demand weakens, Corteva's stock could decline to its 52-week low of $60.54, representing a -30.6% loss from the current price of $87.30. This scenario would likely involve multiple quarters of disappointing earnings, analyst downgrades, and a re-rating to a P/E more in line with historical lows. The maximum drawdown over the past year was -20.9%, but a more severe downturn could approach the 52-week low.
